Literature DB >> 29096730

Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Kristen Stephenson1, Lindsey Kennedy2, Laura Hargrove3, Jennifer Demieville2, Joanne Thomson2, Gianfranco Alpini1, Heather Francis1.   

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a disease of increasing interest, as its prevalence is on the rise. NAFLD has been linked to metabolic syndrome, which is becoming more common due to the Western diet. Because NAFLD can lead to cirrhosis and related complications including hepatocellular carcinoma, the increasing prevalence is concerning, and medical therapy aimed at treating NAFLD is of great interest. Researchers studying the effects of medical therapy on NAFLD use dietary mouse models. The two main types of mouse model diets are the methionine- and choline-deficient (MCD) diet and the Western-like diet (WD). Although both induce NAFLD, the mechanisms are very different. We reviewed several studies conducted within the last 5 years that used MCD diet or WD mouse models in order to mimic this disease in a way most similar to humans. The MCD diet inconsistently induces NAFLD and fibrosis and does not completely induce metabolic syndrome. Thus, the clinical significance of the MCD diet is questionable. In contrast, WD mouse models consisting of high fat, cholesterol, and a combination of high-fructose corn syrup, sucrose, fructose, or glucose not only lead to metabolic syndrome but also induce NAFLD with fibrosis, making these choices most suitable for research.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29096730      PMCID: PMC5860971          DOI: 10.3727/105221617X15093707969658

Source DB:  PubMed          Journal:  Gene Expr        ISSN: 1052-2166


  78 in total

Review 1.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

2.  Serum cholesterol response to dietary cholesterol.

Authors:  A Keys
Journal:  Am J Clin Nutr       Date:  1984-08       Impact factor: 7.045

3.  Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome.

Authors:  Giulio Marchesini; Elisabetta Bugianesi; Gabriele Forlani; Fernanda Cerrelli; Marco Lenzi; Rita Manini; Stefania Natale; Ester Vanni; Nicola Villanova; Nazario Melchionda; Mario Rizzetto
Journal:  Hepatology       Date:  2003-04       Impact factor: 17.425

4.  Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis.

Authors:  Yvette Simon; Sonja M Kessler; Katja Gemperlein; Rainer M Bohle; Rolf Müller; Johannes Haybaeck; Alexandra K Kiemer
Journal:  World J Gastroenterol       Date:  2014-12-21       Impact factor: 5.742

5.  Advanced glycation endproducts induce fibrogenic activity in nonalcoholic steatohepatitis by modulating TNF-α-converting enzyme activity in mice.

Authors:  Joy X Jiang; Xiangling Chen; Hiroo Fukada; Nobuko Serizawa; Sridevi Devaraj; Natalie J Török
Journal:  Hepatology       Date:  2013-08-06       Impact factor: 17.425

6.  Cholesterol and cholate components of an atherogenic diet induce distinct stages of hepatic inflammatory gene expression.

Authors:  Laurent Vergnes; Jack Phan; Merav Strauss; Sherrie Tafuri; Karen Reue
Journal:  J Biol Chem       Date:  2003-08-15       Impact factor: 5.157

Review 7.  Dietary fat and serum lipids: an evaluation of the experimental data.

Authors:  D M Hegsted; L M Ausman; J A Johnson; G E Dallal
Journal:  Am J Clin Nutr       Date:  1993-06       Impact factor: 7.045

8.  Pharmacological inhibition of the chemokine CXCL16 diminishes liver macrophage infiltration and steatohepatitis in chronic hepatic injury.

Authors:  Alexander Wehr; Christer Baeck; Florian Ulmer; Nikolaus Gassler; Kanishka Hittatiya; Tom Luedde; Ulf Peter Neumann; Christian Trautwein; Frank Tacke
Journal:  PLoS One       Date:  2014-11-05       Impact factor: 3.240

9.  MicroRNA profiles following metformin treatment in a mouse model of non-alcoholic steatohepatitis.

Authors:  Akiko Katsura; Asahiro Morishita; Hisakazu Iwama; Joji Tani; Teppei Sakamoto; Miwa Tatsuta; Yuka Toyota; Koji Fujita; Kiyohito Kato; Emiko Maeda; Takako Nomura; Hisaaki Miyoshi; Hirohito Yoneyama; Takashi Himoto; Shintaro Fujiwara; Hideki Kobara; Hirohito Mori; Toshiro Niki; Masafumi Ono; Mitsuomi Hirashima; Tsutomu Masaki
Journal:  Int J Mol Med       Date:  2015-02-06       Impact factor: 4.101

Review 10.  Modeling progressive non-alcoholic fatty liver disease in the laboratory mouse.

Authors:  Jesse D Riordan; Joseph H Nadeau
Journal:  Mamm Genome       Date:  2014-05-07       Impact factor: 2.957

View more
  37 in total

1.  Disruption of hepatic one-carbon metabolism impairs mitochondrial function and enhances macrophage activity in methionine-choline-deficient mice.

Authors:  Brandon J Eudy; Caitlin E McDermott; Gabriel Fernandez; Clayton E Mathews; Jinping Lai; Robin P da Silva
Journal:  J Nutr Biochem       Date:  2020-03-19       Impact factor: 6.048

2.  Triclosan leads to dysregulation of the metabolic regulator FGF21 exacerbating high fat diet-induced nonalcoholic fatty liver disease.

Authors:  Mei-Fei Yueh; Feng He; Chen Chen; Catherine Vu; Anupriya Tripathi; Rob Knight; Michael Karin; Shujuan Chen; Robert H Tukey
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

3.  PBPK modeling of impact of nonalcoholic fatty liver disease on toxicokinetics of perchloroethylene in mice.

Authors:  Chimeddulam Dalaijamts; Joseph A Cichocki; Yu-Syuan Luo; Ivan Rusyn; Weihsueh A Chiu
Journal:  Toxicol Appl Pharmacol       Date:  2020-05-21       Impact factor: 4.219

4.  Molecular and ultrastructure study of endoplasmic reticulum stress in hepatic steatosis: role of hepatocyte nuclear factor 4α and inflammatory mediators.

Authors:  Salwa M Abo El-Khair; Fatma M Ghoneim; Dalia A Shabaan; Ayman Z Elsamanoudy
Journal:  Histochem Cell Biol       Date:  2019-10-21       Impact factor: 4.304

5.  Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice.

Authors:  Kathryn M Spitler; Shwetha K Shetty; Emily M Cushing; Kelli L Sylvers-Davie; Brandon S J Davies
Journal:  Am J Physiol Endocrinol Metab       Date:  2021-08-16       Impact factor: 5.900

6.  Morphological Changes in Major Salivary Glands in Mice Treated With a Choline and Methionine Deficient Diet.

Authors:  Mariana DA Silva Thomaz; Daniel Araki Ribeiro; Jean Nunes Dos Santos; Marcia Regina Nagaoka
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

Review 7.  Nrf2 in liver toxicology.

Authors:  Keiko Taguchi; Thomas W Kensler
Journal:  Arch Pharm Res       Date:  2019-11-28       Impact factor: 4.946

Review 8.  Regulation and functional roles of chemokines in liver diseases.

Authors:  Sheng Cao; Mengfei Liu; Tejasav S Sehrawat; Vijay H Shah
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2021-05-11       Impact factor: 73.082

9.  Zinc Supplementation and Strength Exercise in Rats with Type 2 Diabetes: Akt and PTP1B Phosphorylation in Nonalcoholic Fatty Liver.

Authors:  Ariel Vivero; Manuel Ruz; Matías Rivera; Karen Miranda; Camila Sacristán; Alejandra Espinosa; Juana Codoceo; Jorge Inostroza; Karla Vásquez; Álvaro Pérez; Diego García-Díaz; Miguel Arredondo
Journal:  Biol Trace Elem Res       Date:  2020-09-16       Impact factor: 3.738

10.  Magnesium accumulation upon cyclin M4 silencing activates microsomal triglyceride transfer protein improving NASH.

Authors:  Jorge Simón; Naroa Goikoetxea-Usandizaga; Marina Serrano-Maciá; David Fernández-Ramos; Diego Sáenz de Urturi; Jessica J Gruskos; Pablo Fernández-Tussy; Sofía Lachiondo-Ortega; Irene González-Recio; Rubén Rodríguez-Agudo; Virginia Gutiérrez-de-Juan; Begoña Rodríguez-Iruretagoyena; Marta Varela-Rey; Paula Gimenez-Mascarell; María Mercado-Gomez; Beatriz Gómez-Santos; Carmen Fernandez-Rodriguez; Fernando Lopitz-Otsoa; Maider Bizkarguenaga; Sibylle Dames; Ute Schaeper; Franz Martin; Guadalupe Sabio; Paula Iruzubieta; Javier Crespo; Patricia Aspichueta; Kevan H-Y Chu; Daniela Buccella; César Martín; Teresa Cardoso Delgado; Luis Alfonso Martínez-Cruz; María Luz Martínez-Chantar
Journal:  J Hepatol       Date:  2021-02-09       Impact factor: 25.083

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.